Systematic review of diffuse hemispheric glioma, H3 G34-mutant: Outcomes and associated clinical factors

BACKGROUND: A comprehensive review and description of the clinical features that impact prognosis for patients with diffuse hemispheric glioma, H3 G34-mutant (G34-DHG) is needed. Understanding survival and prognostic features is paramount for clinical advancements and patient care. METHODS: PubMed,...

Descripción completa

Detalles Bibliográficos
Autores principales: Crowell, Cameron, Mata-Mbemba, Daddy, Bennett, Julie, Matheson, Kara, Mackley, Michael, Perreault, Sébastien, Erker, Craig
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9466272/
https://www.ncbi.nlm.nih.gov/pubmed/36105387
http://dx.doi.org/10.1093/noajnl/vdac133
_version_ 1784787958598991872
author Crowell, Cameron
Mata-Mbemba, Daddy
Bennett, Julie
Matheson, Kara
Mackley, Michael
Perreault, Sébastien
Erker, Craig
author_facet Crowell, Cameron
Mata-Mbemba, Daddy
Bennett, Julie
Matheson, Kara
Mackley, Michael
Perreault, Sébastien
Erker, Craig
author_sort Crowell, Cameron
collection PubMed
description BACKGROUND: A comprehensive review and description of the clinical features that impact prognosis for patients with diffuse hemispheric glioma, H3 G34-mutant (G34-DHG) is needed. Understanding survival and prognostic features is paramount for clinical advancements and patient care. METHODS: PubMed, Embase, and Google Scholar were searched for English articles published between January 1, 2012 and June 30, 2021. Eligible studies included patient(s) of any age diagnosed with an H3 G34-mutant brain tumor with at least one measure of survival or progression. Patient-level data were pooled for analyses. This study was prospectively registered in PROSPERO (CRD42021267764) and Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed. RESULTS: Twenty-seven studies met the criteria with a total of 135 patients included. Median age at diagnosis was 15.8 years (interquartile range [IQR]: 13.3–22.0) with 90% having localized disease. Co-occurring alterations included ATRX mutation in 93%, TP53 mutation in 88%, and MGMT promoter methylation in 70%. Median time-to-progression was 10.0 months (IQR: 6.0–18.0) and median overall survival was 17.3 months (95% CI: 15.0 to 22.9). The median time from progression to death was 5.0 months (IQR: 3.0–11.7). Factors associated with survival duration were age, as patients ≥18 y/o demonstrated longer survival (hazard ratio [HR] =2.05, 95% CI: 1.16 to 3.62), and degree of upfront resection, as near or gross-total resection demonstrated longer survival compared to those with less than near-total resection (HR = 3.75, 95% CI: 2.11 to 6.62). CONCLUSION: This systematic review highlights available clinical data for G34-DHG demonstrating poor outcomes and important prognostic features, while serving as a baseline for future research and clinical trials.
format Online
Article
Text
id pubmed-9466272
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-94662722022-09-13 Systematic review of diffuse hemispheric glioma, H3 G34-mutant: Outcomes and associated clinical factors Crowell, Cameron Mata-Mbemba, Daddy Bennett, Julie Matheson, Kara Mackley, Michael Perreault, Sébastien Erker, Craig Neurooncol Adv Meta-Analysis BACKGROUND: A comprehensive review and description of the clinical features that impact prognosis for patients with diffuse hemispheric glioma, H3 G34-mutant (G34-DHG) is needed. Understanding survival and prognostic features is paramount for clinical advancements and patient care. METHODS: PubMed, Embase, and Google Scholar were searched for English articles published between January 1, 2012 and June 30, 2021. Eligible studies included patient(s) of any age diagnosed with an H3 G34-mutant brain tumor with at least one measure of survival or progression. Patient-level data were pooled for analyses. This study was prospectively registered in PROSPERO (CRD42021267764) and Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were followed. RESULTS: Twenty-seven studies met the criteria with a total of 135 patients included. Median age at diagnosis was 15.8 years (interquartile range [IQR]: 13.3–22.0) with 90% having localized disease. Co-occurring alterations included ATRX mutation in 93%, TP53 mutation in 88%, and MGMT promoter methylation in 70%. Median time-to-progression was 10.0 months (IQR: 6.0–18.0) and median overall survival was 17.3 months (95% CI: 15.0 to 22.9). The median time from progression to death was 5.0 months (IQR: 3.0–11.7). Factors associated with survival duration were age, as patients ≥18 y/o demonstrated longer survival (hazard ratio [HR] =2.05, 95% CI: 1.16 to 3.62), and degree of upfront resection, as near or gross-total resection demonstrated longer survival compared to those with less than near-total resection (HR = 3.75, 95% CI: 2.11 to 6.62). CONCLUSION: This systematic review highlights available clinical data for G34-DHG demonstrating poor outcomes and important prognostic features, while serving as a baseline for future research and clinical trials. Oxford University Press 2022-08-19 /pmc/articles/PMC9466272/ /pubmed/36105387 http://dx.doi.org/10.1093/noajnl/vdac133 Text en © The Author(s) 2022. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Meta-Analysis
Crowell, Cameron
Mata-Mbemba, Daddy
Bennett, Julie
Matheson, Kara
Mackley, Michael
Perreault, Sébastien
Erker, Craig
Systematic review of diffuse hemispheric glioma, H3 G34-mutant: Outcomes and associated clinical factors
title Systematic review of diffuse hemispheric glioma, H3 G34-mutant: Outcomes and associated clinical factors
title_full Systematic review of diffuse hemispheric glioma, H3 G34-mutant: Outcomes and associated clinical factors
title_fullStr Systematic review of diffuse hemispheric glioma, H3 G34-mutant: Outcomes and associated clinical factors
title_full_unstemmed Systematic review of diffuse hemispheric glioma, H3 G34-mutant: Outcomes and associated clinical factors
title_short Systematic review of diffuse hemispheric glioma, H3 G34-mutant: Outcomes and associated clinical factors
title_sort systematic review of diffuse hemispheric glioma, h3 g34-mutant: outcomes and associated clinical factors
topic Meta-Analysis
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9466272/
https://www.ncbi.nlm.nih.gov/pubmed/36105387
http://dx.doi.org/10.1093/noajnl/vdac133
work_keys_str_mv AT crowellcameron systematicreviewofdiffusehemisphericgliomah3g34mutantoutcomesandassociatedclinicalfactors
AT matambembadaddy systematicreviewofdiffusehemisphericgliomah3g34mutantoutcomesandassociatedclinicalfactors
AT bennettjulie systematicreviewofdiffusehemisphericgliomah3g34mutantoutcomesandassociatedclinicalfactors
AT mathesonkara systematicreviewofdiffusehemisphericgliomah3g34mutantoutcomesandassociatedclinicalfactors
AT mackleymichael systematicreviewofdiffusehemisphericgliomah3g34mutantoutcomesandassociatedclinicalfactors
AT perreaultsebastien systematicreviewofdiffusehemisphericgliomah3g34mutantoutcomesandassociatedclinicalfactors
AT erkercraig systematicreviewofdiffusehemisphericgliomah3g34mutantoutcomesandassociatedclinicalfactors